Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Franck Morschhauser,Gilles Salles,Pamela McKay,Hervé Tilly,Anna Schmitt,John F. Gerecitano,Peter Johnson,Steven Le Gouill,Michael Dickinson,Christophe Fruchart,Thierry Lamy,Aristeidis Chaidos,Wojciech Jurczak,Stephen Opat,John Radford,Pier Luigi Zinzani,Sarit Assouline,Guillaume Cartron,Alicia Clawson, Natasha Picazio,Scott Ribich,Stephen J. Blakemore,John Larus,Harry Miao, Mark Woodruff,Peter T.C. Ho,Vincent Ribrag

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2017）

Cited 3|Views13
No score
Abstract
New treatments with novel mechanisms of action are needed for patients with relapsed/refractory (R/R) DLBCL and FL. These tumor cells may depend on the histone methyltransferase EZH2 to perpetuate a less-differentiated state, and activating mutations may be oncogenic drivers. Tazemetostat, a potent, selective EZH2 inhibitor, shows antitumor activity in preclinical models and a phase 1 study in patients (pts) with mutated or wild-type (wt) EZH2 tumors.
More
Translated text
Key words
ezh2 inhibitor,tazemetostat,b-cell,non-hodgkin
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined